- Home
- HTH vs CGON Comparison
HTH vs CGON Comparison
Compare HTH & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTH
- CGON
- Stock Information
- Founded
- HTH 1998
- CGON 2010
- Country
- HTH United States
- CGON United States
- Employees
- HTH N/A
- CGON N/A
- Industry
- HTH Major Banks
- CGON
- Sector
- HTH Finance
- CGON
- Exchange
- HTH Nasdaq
- CGON NYSE
- Market Cap
- HTH 2.0B
- CGON 2.3B
- IPO Year
- HTH 2004
- CGON 2024
- Fundamental
- Price
- HTH $32.48
- CGON $36.76
- Analyst Decision
- HTH Hold
- CGON Strong Buy
- Analyst Count
- HTH 3
- CGON 7
- Target Price
- HTH $34.50
- CGON $64.43
- AVG Volume (30 Days)
- HTH 341.5K
- CGON 840.8K
- Earning Date
- HTH 10-24-2024
- CGON 11-02-2024
- Dividend Yield
- HTH 2.11%
- CGON N/A
- EPS Growth
- HTH 11.75
- CGON N/A
- EPS
- HTH 1.75
- CGON N/A
- Revenue
- HTH $1,175,609,000.00
- CGON $539,000.00
- Revenue This Year
- HTH N/A
- CGON $396.08
- Revenue Next Year
- HTH $3.16
- CGON $414.92
- P/E Ratio
- HTH $18.66
- CGON N/A
- Revenue Growth
- HTH N/A
- CGON N/A
- 52 Week Low
- HTH $26.78
- CGON $25.77
- 52 Week High
- HTH $35.66
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- HTH 58.28
- CGON 51.85
- Support Level
- HTH $30.97
- CGON $33.49
- Resistance Level
- HTH $32.94
- CGON $38.30
- Average True Range (ATR)
- HTH 0.59
- CGON 1.43
- MACD
- HTH 0.14
- CGON 0.05
- Stochastic Oscillator
- HTH 82.71
- CGON 59.32
About HTH Hilltop Holdings Inc.
Hilltop Holdings Inc is a Dallas-based financial holding company. Its primary line of business is to provide business and consumer banking services from offices throughout Texas through the PlainsCapital Bank. The company also provides other financial products and services through its broker-dealer and mortgage origination segments. The company generates a majority of its revenue through its banking operations.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.